Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors

Journal of Nuclear Medicine- China

doi 10.2967/jnumed.113.123190

Full Text

Abstract

Available in

Date

Authors

Publisher

Society of Nuclear Medicine

Related search

Peptide Receptor Radionuclide Therapy

Best Practice and Research in Clinical Gastroenterology
Gastroenterology
2005English

Peptide Receptor Radionuclide Therapy

2007English

New Developments in Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Predictors of Long-Term Outcome in Patients With Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2014English

Peptide Receptor Radionuclide Therapy Plus Somatostatin Analogues for a Neuroendocrine Tumour Combined and Maintenance Treatment

Clinical and Translational Imaging
Nuclear MedicineRadiologyImaging
2019English

Reply: Peptide Receptor Radionuclide Therapy in the United States

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2012English

DNA Damage in Blood Lymphocytes in Patients After 177Lu Peptide Receptor Radionuclide Therapy

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2015English

Peptide Receptor Radionuclide Therapy in Patients With Medullary Thyroid Carcinoma: Predictors and Pitfalls

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

68Ga-Dotatate PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients With Well-Differentiated Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy